DALLAS, TX — March 26, 2002 — For the first time, researchers have shown that people who are Aspirin (acetylsalicylic acid)-resistant have a higher risk of dying from heart disease than people who are not Aspirin-resistant, according to a study in today's rapid access issue of Circulation: Journal of the American Heart Association.
Aspirin blocks the formation of thromboxane A2, a chemical in the body that makes platelets sticky and promotes blood clotting. However, lead author John W. Eikelboom, MBBS, says it appears that Aspirin does not effectively block thromboxane synthesis in some people. This makes them resistant to the protective effects of the drug.
In the study, patients taking Aspirin who had a high level of thromboxane in their urine had a 3.5 times higher risk of cardiovascular death than patients who had the lowest level says Dr. Eikelboom, a clinical lecturer at the University of Western Australia, Royal Perth Hospital, Perth, Australia.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!